Profile data is unavailable for this security.
About the company
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
- Revenue in USD (TTM)0.00
- Net income in USD-127.16m
- Incorporated2017
- Employees87.00
- LocationCelcuity Inc16305 36th Ave N Ste 100MINNEAPOLIS 55446-4285United StatesUSA
- Phone+1 (763) 392-0767
- Fax+1 (302) 655-5049
- Websitehttps://www.celcuity.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tourmaline Bio Inc | 0.00 | -82.87m | 424.89m | 74.00 | -- | 1.52 | -- | -- | -3.22 | -3.22 | 0.00 | 10.90 | 0.00 | -- | -- | 0.00 | -25.63 | -26.41 | -26.13 | -27.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -73.80 | -- | -56.26 | -- |
| aTyr Pharma Inc | 0.00 | -63.41m | 447.69m | 56.00 | -- | 5.97 | -- | -- | -0.8061 | -0.8061 | 0.00 | 0.8432 | 0.00 | -- | -- | 0.00 | -60.25 | -47.98 | -68.85 | -54.91 | -- | -- | -- | -978.90 | -- | -- | 0.017 | -- | -33.43 | -11.05 | -27.06 | -- | -3.83 | -- |
| Fortrea Holdings Inc | 2.69bn | -754.60m | 450.69m | 15.00k | -- | 0.5248 | -- | 0.1678 | -8.39 | -8.79 | 29.91 | 9.49 | 0.7297 | -- | 3.22 | -- | -20.50 | -- | -27.22 | -- | 20.21 | -- | -28.10 | -- | -- | -0.5045 | 0.5856 | -- | -5.14 | -- | -756.47 | -- | -- | -- |
| Cullinan Therapeutics Inc | 0.00 | -178.74m | 457.95m | 111.00 | -- | 0.8254 | -- | -- | -3.09 | -3.09 | 0.00 | 9.40 | 0.00 | -- | -- | 0.00 | -34.74 | -16.54 | -36.48 | -17.34 | -- | -- | -- | -1,797.10 | -- | -- | 0.00 | -- | -- | -- | -9.28 | -- | -- | -- |
| Organogenesis Holdings Inc | 458.76m | -20.43m | 465.55m | 869.00 | -- | 1.92 | -- | 1.01 | -0.1621 | -0.1621 | 3.51 | 2.90 | 0.991 | 3.88 | 4.60 | 527,917.10 | -3.43 | 6.65 | -4.08 | 8.18 | 75.85 | 75.66 | -3.46 | 6.14 | 3.67 | 75.23 | 0.0043 | 0.00 | 11.29 | 13.06 | -118.95 | -- | 9.98 | -- |
| Septerna Inc | 977.00k | -79.11m | 467.15m | 75.00 | -- | 1.17 | -- | 478.15 | -9.91 | -9.91 | 0.0323 | 9.01 | -- | -- | -- | 13,026.67 | -- | -- | -- | -- | -- | -- | -8,097.03 | -- | -- | -- | 0.00 | -- | 611.92 | -- | -12,762.79 | -- | -- | -- |
| Celcuity Inc | 0.00 | -127.16m | 474.84m | 87.00 | -- | 5.47 | -- | -- | -3.03 | -3.03 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.59 | -42.61 | -71.30 | -45.75 | -- | -- | -- | -- | -- | -492.78 | 0.532 | -- | -- | -- | -75.26 | -- | -8.05 | -- |
| Bicara Therapeutics Inc | 0.00 | -92.33m | 475.01m | 55.00 | 0.6139 | 1.03 | -- | -- | 14.19 | 14.19 | 0.00 | 8.42 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.80 | -- | -- | -- |
| Tyra Biosciences Inc | 0.00 | -96.44m | 483.92m | 60.00 | -- | 1.49 | -- | -- | -1.63 | -1.63 | 0.00 | 6.09 | 0.00 | -- | -- | 0.00 | -25.78 | -24.74 | -26.59 | -25.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -25.09 | -- | 101.48 | -- |
| Kura Oncology Inc | 67.99m | -181.89m | 490.88m | 192.00 | -- | 1.26 | -- | 7.22 | -2.09 | -2.09 | 0.7812 | 4.51 | 0.1048 | -- | -- | 354,119.80 | -28.03 | -26.38 | -30.94 | -28.06 | -- | -- | -267.52 | -1,266.72 | -- | -- | 0.0256 | -- | -- | -- | -13.99 | -- | -- | -- |
| Mind Medicine (MindMed) Inc | 0.00 | -77.63m | 494.87m | 74.00 | -- | 2.22 | -- | -- | -0.9449 | -0.9449 | 0.00 | 2.95 | 0.00 | -- | -- | 0.00 | -28.18 | -55.68 | -34.11 | -63.31 | -- | -- | -- | -- | -- | -- | 0.09 | -- | -- | -- | -13.52 | -- | -- | -- |
| Bicycle Therapeutics PLC (ADR) | 25.72m | -203.22m | 501.40m | 305.00 | -- | 0.6768 | -- | 19.49 | -3.13 | -3.13 | 0.3968 | 10.70 | 0.036 | -- | 378.26 | 84,334.43 | -28.40 | -26.61 | -30.70 | -29.60 | -- | -- | -790.07 | -587.28 | -- | -- | 0.0013 | -- | 30.76 | 20.65 | 6.44 | -- | -4.50 | -- |
| Capricor Therapeutics Inc | 17.36m | -55.06m | 509.64m | 160.00 | -- | 3.99 | -- | 29.35 | -1.42 | -1.42 | 0.4477 | 2.79 | 0.1709 | -- | 80.98 | 108,522.40 | -54.19 | -45.52 | -71.29 | -61.91 | -- | -- | -317.13 | -248.15 | -- | -- | 0.0258 | -- | -11.55 | 85.83 | -81.57 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 31 Mar 2025 | 4.26m | 11.47% |
| BVF Partners LPas of 31 Mar 2025 | 3.47m | 9.34% |
| Soleus Capital Management LP (Investment Management)as of 31 Mar 2025 | 2.57m | 6.93% |
| Perceptive Advisors LLCas of 31 Mar 2025 | 2.36m | 6.36% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 2.03m | 5.46% |
| The Vanguard Group, Inc.as of 31 Mar 2025 | 1.63m | 4.40% |
| Eventide Asset Management LLCas of 31 Mar 2025 | 1.27m | 3.41% |
| Saturn V Capital Management LPas of 31 Mar 2025 | 1.09m | 2.95% |
| Citadel Advisors LLCas of 31 Mar 2025 | 927.21k | 2.50% |
| Braidwell LPas of 31 Mar 2025 | 884.31k | 2.38% |
